Free Trial
NASDAQ:ZYXI

Zynex (ZYXI) Stock Price, News & Analysis

Zynex logo
$2.35 -0.34 (-12.64%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$2.40 +0.05 (+2.34%)
As of 07/3/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Zynex Stock (NASDAQ:ZYXI)

Key Stats

Today's Range
$2.31
$2.67
50-Day Range
$1.66
$2.69
52-Week Range
$1.66
$10.62
Volume
243,216 shs
Average Volume
174,162 shs
Market Capitalization
$71.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Zynex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

ZYXI MarketRank™: 

Zynex scored higher than 53% of companies evaluated by MarketBeat, and ranked 1480th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zynex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Zynex has only been the subject of 2 research reports in the past 90 days.

  • Read more about Zynex's stock forecast and price target.
  • Earnings Growth

    Earnings for Zynex are expected to grow by 135.00% in the coming year, from $0.20 to $0.47 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zynex is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zynex is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zynex has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zynex's valuation and earnings.
  • Percentage of Shares Shorted

    22.34% of the float of Zynex has been sold short.
  • Short Interest Ratio / Days to Cover

    Zynex has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zynex has recently decreased by 0.25%, indicating that investor sentiment is improving.
  • Dividend Yield

    Zynex does not currently pay a dividend.

  • Dividend Growth

    Zynex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.34% of the float of Zynex has been sold short.
  • Short Interest Ratio / Days to Cover

    Zynex has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zynex has recently decreased by 0.25%, indicating that investor sentiment is improving.
  • News Sentiment

    Zynex has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Zynex this week, compared to 7 articles on an average week.
  • MarketBeat Follows

    2 people have added Zynex to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zynex insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    49.28% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 29.68% of the stock of Zynex is held by institutions.

  • Read more about Zynex's insider trading history.
Receive ZYXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter.

ZYXI Stock News Headlines

Zynex stock falls after Tricare extends payment suspension
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Tricare Temporary Payment Suspension Update
Zynex (NASDAQ:ZYXI) Receives Buy Rating from HC Wainwright
Zynex appoints Steven Dyson as new CEO
Zynex taps Steve Dyson as chief executive officer
Zynex Announces Steven Dyson as New CEO
See More Headlines

ZYXI Stock Analysis - Frequently Asked Questions

Zynex's stock was trading at $8.01 on January 1st, 2025. Since then, ZYXI stock has decreased by 70.7% and is now trading at $2.35.

Zynex Inc. (NASDAQ:ZYXI) released its quarterly earnings data on Monday, April, 28th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.09. The firm had revenue of $26.58 million for the quarter, compared to analysts' expectations of $30.83 million. Zynex had a negative net margin of 4.30% and a negative trailing twelve-month return on equity of 23.70%.
Read the conference call transcript
.

Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zynex investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
4/28/2025
Today
7/04/2025
Next Earnings (Estimated)
7/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:ZYXI
Fax
N/A
Employees
770
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+155.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
11.75
P/E Growth
N/A
Net Income
$2.99 million
Pretax Margin
-5.91%

Debt

Sales & Book Value

Annual Sales
$192.35 million
Cash Flow
$0.21 per share
Price / Cash Flow
11.02
Book Value
$1.12 per share
Price / Book
2.10

Miscellaneous

Free Float
15,337,000
Market Cap
$71.06 million
Optionable
Optionable
Beta
0.83
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ZYXI) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners